recurrence risk


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to recurrence risk: Relative risk

re·cur·rence risk

risk that a disease will occur elsewhere in a pedigree, given that at least one member of the pedigree (the proband) exhibits the disease.

re·cur·rence risk

(rĕ-kŭr'ĕns risk)
Chance or possibility that a disease will occur elsewhere in a pedigree, given that at least one member of the pedigree (the proband) exhibits the disease.
References in periodicals archive ?
A recent meta-analysis demonstrated a strong reduction of the recurrence risk when immunosuppressive drugs were added to standard ATD treatment in GD patients, and the reduction of the recurrence risk was similar in studies using corticosteroid and noncorticosteroid immunosuppressive drugs [30].
In this study, dichotomization of clinicopathologic variables by AUC enabled quick and easy differentiation of variables associated with high and low recurrence risk. However, variations in breast cancer recurrence are rarely affected by a single factor.
In other words, country-specific effects are crucial in measuring conflict recurrence risk. Another important conceptual distinction between this paper and earlier studies is the timing of the model, as we infer the risk of conflict recurrence at time t+1 by using the available information set at time t, which is an abstraction and not burdened by the problem of endogeneity often present in conflict regressions.
Our study shows a slightly higher recurrence risk of 34.85%, Nelson et al18 similarly documented a cumulative recurrence risk of 34.9%.
Germinal mosaicism increases the recurrence risk for "new" Duchenne muscular dystrophy mutations.
First, because of small numbers and the study's design, no statistical tests were performed, and recurrence risk could not be estimated.
It is important to recognise this to allow for accurate recurrence risk estimation and genetic counselling.
The rate of recurrence of the AF following a successful ECV especially increases in LAVI values over 36mL/[m.sup.2], and every 1mL/[m.sup.2] increase in the LAVI was found to increase the recurrence risk of the AF by 35%.
Data for patients with secondary VTE do demonstrate an increased recurrence risk; when we excluded patients with cancer, the RVO studies were no longer predictive (P = 0.12).
Parents can be reassured that the recurrence risk for future pregnancies is low, as most affected individuals have de novo mutations.
Therefore the choice of adjuvant should be according to the environmental conditions, individual recurrence risk factors and the surgeon's expertise.